Products & Services
Applications

Applications

Nanopore sequencing offers advantages in all areas of research. Our offering includes DNA sequencing, as well as RNA and gene expression analysis and future technology for analysing proteins.

Learn about applications
View all Applications
Resources
News Explore
Careers Contact

Executive team

The Oxford Nanopore executive team has combined experience in the development, manufacture and commercialisation of disruptive technologies including DNA sequencing. This includes a corporate function to support the Company's past and future fundraising activities.

Dr Gordon Sanghera

Chief Executive Officer

Dr Gordon Sanghera - Chief Executive Officer
Close this dialog

Dr Gordon Sanghera

Chief Executive Officer

Gordon Sanghera was co-founder of Oxford Nanopore, together with Hagan Bayley and IP Group. He was appointed CEO in June 2005. He brings over 20 years' experience in the design, development and global launch of disruptive platform sensor technologies.

Dr Sanghera’s PhD in bioelectronics sensing was followed by a career at MediSense an Oxford spin-out that delivered a new generation glucose technology to the market.  Following the acquisition of MediSense by Abbott Laboratories  Dr Sanghera held both UK and US VP and Director-level positions, including VP World Wide Marketing, Research Director and Manufacturing Process Development Director. Before its acquisition by Abbott, Gordon led the R&D of Medisense Inc. where he was instrumental in the launch of several generations of blood glucose bio-electronic systems for the consumer and hospital medical markets. He has also developed and validated production processes to meet with the regulatory requirements for USA and Europe.

Gordon has a PhD in bio-electronic technology and a degree in Chemistry.
Read the article about Dr Sanghera in the Financial Times. 

Dr Spike Willcocks

Chief Strategy Officer

Dr Spike Willcocks - Vice President, Business and Corporate Development
Close this dialog

Dr Spike Willcocks

Chief Strategy Officer

After completing an MA in Chemistry and a DPhil in Biochemistry at the University of Oxford, Dr Willcocks became one of the initial members of IPGroup Plc following its landmark deal with the Chemistry Department at Oxford. Ultimately leading the Life Science team, Dr Willcocks' role encompassed all aspects of technology commercialisation, including spin-out company formation and business and corporate development, as well as private and public equity financings.

Dr Willcocks was a key player in the creation of 14 life science businesses based on technology from three universities, leading proposals for the investment of £4m in seed financing from IPGroup and holding positions of Director and Chairman for 6 portfolio companies. Working alongside the executive teams of the portfolio companies, Dr Willcocks played an integral role in out-licensing transactions, co-development deals and acquisitions. As well as supporting fundraisings for portfolio biotechnology companies, raising an aggregate of £20m, Dr Willcocks also assisted with IPGroup's own IPO in October 2003 on the LSE, raising £30m and capitalising the company at over £100m. Dr Willcocks was actively involved in the establishment of ONL whilst at IPGroup before joining full time in January 2006.

He is also a leading real tennis player, and regularly competes in international tournaments.

Clive Brown

Chief Technology Officer

Clive Brown - Chief Technology Officer
Close this dialog

Clive Brown

Chief Technology Officer

Clive Brown is CTO of Oxford Nanopore, where he leads the innovation of breakthrough technologies and product development, that are designed to enable the analysis of anything, by anyone, anywhere.

Clive has held a variety of roles in Genomics and Genetic R&D, he also played a key role in developing the Solexa NGS platform that is now the basis for Illumina’s sequencing technology.

Dr John Milton

Chief Scientific Officer

Dr John Milton - Chief Scientific Officer
Close this dialog

Dr John Milton

Chief Scientific Officer

John is Chief Scientific Officer at Oxford Nanopore. He joined the company in 2008 and has been instrumental in our growth from a start-up company spun out from Oxford University to a global presence in the DNA sequencing technology market.
 
A member of the executive team, John initially built and recruited our chemical and biological research departments, putting in place a research pipeline capable of rapidly designing and producing high quality nanopore proteins, enzymes, chemicals and other materials essential for our technology R&D programmes.
 
John joined us from Solexa (2001-2006), where, as Senior Director of R&D, he designed and built the Reversible Terminator chemistry that lies at the heart of Illumina's sequencing systems.
 
At Solexa, as at Oxford Nanopore, John built up and managed large multidisciplinary scientific teams across a range of technical disciplines. His work in this field led to the scale-up and production of the chemical sequencing reagents for commercial launch of the Solexa sequencing system which was sold to Illumina in 2007 for $650million.
 
More recently, John has initiated new R&D efforts looking at future technologies that will complement our nanopore sequencing technology.
 
John holds a PhD in Chemistry (1991, University of Liverpool) and, following two years of postdoctoral work at Leeds University, spent a decade working in R& D in the pharmaceutical sector.
 
In 2018 John was awarded the Potts Science Medal for outstanding lifetime contribution to Chemistry.

John Schoellerman

SVP, Corporate Development and Investment

John Schoellerman
Close this dialog

John Schoellerman

SVP, Corporate Development and Investment

John joined Oxford Nanopore in 2019 as SVP of Corporate Development and Investment
 
Together with the executive leadership team, John works on a range of fundraising and partnering activities aimed at scaling the business and tapping new growth opportunities for Oxford Nanopore’s technology.
 
Previously a Managing Director and head of the Medtech practice at Lazard, John led a broad range of strategic transactions for clients in the US, Europe and Asia.   He has also worked in healthcare investment banking at J.P. Morgan in San Francisco, London and New York.  John started his career at Hambrecht & Quist in San Francisco.
John holds a BA from Harvard and an MBA from INSEAD.

Tim Cowper

Chief Financial Officer

Tim Cowper - VP, Finance
Close this dialog

Tim Cowper

Chief Financial Officer

A Chartered Accountant and operations specialist, Tim was interim Finance Director at Oxford Nanopore for several months in 2009, handing over a stable and well documented finance infrastructure. He then joined Oxford Nanopore as Commercial Operations Director in 2012.

In his first five years at the company Tim was responsible for setting up and managing operations and infrastructure across the company, including leading on operations for our first product launch – the MinION Access Programme – in 2015.

As part of his Operations role, Tim selected and implemented our Enterprise Resource Planning system which has remained robust and fit for purpose throughout the company's rapid growth and development.

Tim was appointed as VP-Finance in 2017 and continues to ensure that Oxford Nanopore’s values of agility and entrepreneurialism are reflected in our corporate governance, risk control and business processes, to maximise business efficiency.

Having qualified as an accountant at Ernst & Young, Tim became Financial Controller of Celltech Group plc where he was a key member of the IPO team and managed several transactions of the Listed company. He went on to co-found Sterilox and ran the finance function before joining Clipper Ventures plc as Finance Director. Tim has also been Finance Director at British Biotech plc (Vernalis plc) as well as managing a portfolio of biotech and technology companies, including the AIM-listed Bioventix plc, before joining Oxford Nanopore.

Zoe McDougall

VP, Marketing and Corporate Affairs

Zoe McDougall, VP, Marketing and Corporate Affairs
Close this dialog

Zoe McDougall

VP, Marketing and Corporate Affairs

Zoe joined Oxford Nanopore in 2008 in a strategic marketing, communications and investor facing role - the first person to be hired with a specific commercial remit.  She now leads our Commercial & Corporate Marketing and Corporate Affairs functions. 
 
Since the foundation of the company she has driven accessible and authentic communities and communication channels so anyone engaging with, or interested in, Oxford Nanopore understands the company, our technology and our philosophy, whatever the length or nature of their relationship with us.  This supports sales and utilisation of the technology, as well as fundraising and investor relations. The Company has raised £613 million to date.   
 
During early commercialisation, Zoe and her team drove the creation of structures and activities that support the building up of Oxford Nanopore’s customer community; this enables many teams at Oxford Nanopore to collaborate with our thriving user base, to improve the technology and expand the applications that it can perform.
 
Zoe started her career in sales and marketing at SmithKline Beecham.  She subsequently worked at the strategic marketing and communications consultancy Porter Novelli where she ran healthcare-related campaigns across a range of clinical areas for clients including GSK, BMS and Pfizer, across multiple areas including immunology, cancer, diabetes, cardiovascular and respiratory medicine.
 
Before joining Oxford Nanopore Zoe worked on the IPO and investor relations for a UK specialty pharma company. In 2004 she spent six months working with a medical humanitarian organisation in Sri Lanka.

Jordan Herman

SVP, General Counsel

Jordan Herman - VP, General Counsel
Close this dialog

Jordan Herman

SVP, General Counsel

Jordan Herman joined Oxford Nanopore in 2021 as General Counsel. Prior to this Jordan was a partner at Baker Botts L.L.P., where he was our outside counsel for over a decade. He’s long been involved in supporting our growth from a dozen people to a global company; from an idea to an industry leading technology.

Jordan leads our growing in-house legal team, and his responsibilities reflect our growth journey both corporately and commercially. His main remit is to ensure his team have the desire and ability to enable the company to grow, flourish and innovate while remaining legal, ethical and reflecting our values.

Jordon’s role includes supporting and collaborating with leadership team, overseeing the legal department, negotiating legal transactions and identifying and managing risk. He and his team are also working on strengthening internal controls, simplifying our terms and conditions and establishing processes for global monitoring and compliance.

Jordan has many years’ experience in areas including technology transfer and commercial agreements, M&A, joint ventures, licensing, and venture capital. He has worked across the life science, software, medical device and digital media industries, supporting high growth businesses in the US, Europe and around the world.

Jordan was most recently Baker Botts L.L.P., Chair of the Austin Office Corporate Department and Co-Chair of the Life Sciences group. He JD from The Ohio State University, following which he clerked for the Hon. James Rosenbaum, formerly, Chief Judge for the U.S. District Court, District of Minnesota. Jordan also has a degree in Political Economy from Washington University.

 

Open a chat to talk to our sales team